The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …

Therapies with genetically modified T cells that express chimeric antigen receptors (CARs)
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …

Background Immunotherapy with chimeric antigen receptor (CAR)–expressing T cells that
target the disialoganglioside GD2 expressed on tumor cells may be a therapeutic option for …

Chimeric antigen receptor (CAR) T cell therapy has emerged as a cancer treatment with
enormous potential, demonstrating impressive antitumor activity in the treatment of …

CD19-and B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T
cells have enabled unprecedented responses in a subset of refractory patients with B-cell …

The success of chimeric antigen receptor (CAR) T cells targeting B-cell malignancies
propelled the field of synthetic immunology and raised hopes to treat solid tumors in a …

Acute myeloid leukemia (AML) poses a singular challenge for chimeric antigen receptor
(CAR) therapy owing to its phenotypic heterogeneity and similarity to normal hematopoietic …

While the adoption of multimodal therapy including surgery, radiation, and aggressive
combination chemotherapy has improved outcomes for many children with high-risk …

Chimeric antigen receptor T (CAR-T) cell therapy has significantly improved the life
expectancy for patients with refractory or relapse B cell lymphoma. As for B cell acute …

T cell differentiation is a highly regulated, multi-step process necessary for the progressive
establishment of effector functions, immunological memory, and long-term control of …